



Rejse gennem PCa

Ahmed H. Zedan

H-læge, onkologisk afd., VS

PhD studerende, urologisk afd., VS





165 år tilbage

Medical Societies.

ROYAL MEDICAL AND CHIRURGICAL SOCIETY.

TUESDAY, APRIL 12, 1853.—DR. COPLAND, PRESIDENT.

A paper was read, entitled

opium WITH little benefit. The body was not examined, but ne (Mr. Hawkins) had no doubt the disease was situated in the prostate gland.

Mr. HOLMES COOTE remarked that great interest attached to Mr. Adams's case from the fact of its being genuine scirrhus of the prostate gland—a **disease of very rare occurrence**, whilst fungous disease of that body was not uncommon. Scirrhus was common in the mammary gland, but uncommon in other situations. He believed that in Mr. Adams's case the absence of haemorrhage was owing to the fact of there being no abrasion of the mucous membrane present. Haemorrhage was common in

Examination of the body.—The lumbar glands were enlarged by the infiltration of scirrhus; so also the lymphatic glands of the pelvis. There were cysts containing pus near the symphysis pubis. The prostate gland was enlarged to nearly twice its natural size: an ovoid mass, *distinctly scirrhous* the size of a small nut.

2016


Nye Kræfttilfælde i Danmark

Cancerregisteret

Incidensrate-andelen i 2015 (mænd) er 20,3 pct.

Prostatakræft er den hyppigst diagnosticerede kræftsygdom hos mænd.
Sygdommen ses især efter 60-års alderen.

Efter at være steget betydeligt fra 2006 til 2009, hvor incidensraten toppede
~~med 170,8 per 100.000~~, har den i de følgende år et stanset fald i



2015

Hele vesten


Estimated New Cases

			Males	Females		
Prostate	180,890	21%		Breast	246,660	29%
Lung & bronchus	117,920	14%		Lung & bronchus	106,470	13%
Colon & rectum	70,820	8%		Colon & rectum	63,670	8%
Urinary bladder	58,950	7%		Uterine corpus	60,050	7%
Melanoma of the skin	46,870	6%		Thyroid	49,350	6%
Non-Hodgkin lymphoma	40,170	5%		Non-Hodgkin lymphoma	32,410	4%
Kidney & renal pelvis	39,650	5%		Melanoma of the skin	29,510	3%
Oral cavity & pharynx	34,780	4%		Leukemia	26,050	3%
Leukemia	34,090	4%		Pancreas	25,400	3%
Liver & intrahepatic bile duct	28,410	3%		Kidney & renal pelvis	23,050	3%
All Sites	841,390	100%		All Sites	843,820	100%




Hvad var der sket!





Medicinisk



kirurgisk, Stråle



Medicinsk




1780'er-1890'er



Palmer, J. F. (ed.) The Works of John Hunter F. R. S. with Notes (Longman, London, 1786)

White, W. J. Surgical removal of the hypertrophied prostate. Ann. Surg. 152 (1893)

1941



the primary lesion, increased density of the metastatic lesions in the roentgenograms and in 1 case improvement in neurologic signs of compression of the cauda equina by metastases. The improvement was greater than we have observed in any case in which far advanced or metastatic cancer was treated in any other way. It is certain that in many cases regression of the neoplasm is not complete.

Untoward effects of castration were temporary swelling of the ankles, development of hot flashes and abolition of sexual capacity. The hot flashes were eliminated by administering estrogen.

Injections of androgen caused an increase of pain.


950 East Fifty-Ninth Street.

1960s



Anderson, K. M. & Liao, S. Selective retention of dihydrotestosterone by prostatic nuclei. *Nature* 219,277–279 (1968).

1970s-1980s



Schally, A. V., Kastin, A. J. & Arimura, A. Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies. *Fertil. Steril.* 22, 703–721 (1971).

Liao, S., Howell, D. K. & Chang, T. M. Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 α -dihydrotestosterone in rat ventral prostate. *Endocrinology* 94, 1205–1209 (1974).

Tolis, G. et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. *Proc. Natl Acad. Sci.* 79, 1658–1662 (1982).



1980-1995





1995-2000s





2014-2017

MEDIAN SURVIVAL FROM FIRST LIFE-EXTENDING THERAPY

1990s

- Prednisone (P) alone (mCRPC): **12.6** mo¹

2004

- TAX327 (DOC/P - mCRPC): **18.9** mo²

2010

- TROPIC (DOC/P → CABP/P – M1 CRPC): **29.4** mo³⁻⁴

2011

- COU-AA-301 (DOC/P → ABI/P – M1 CRPC): **32.6** mo⁵

2013

- COU-AA-302 (ABI/P pre-DOC – M1 CRPC): **34.7** mo⁵

2014

- PREVAIL (ENZA pre-DOC – M1 CRPC): **35.3** mo⁶

2015

- CHARTED (ADT+DOC – M1 HSPC): **57.6** mo⁷

2016

- STAMPEDE (ADT+DOC/P – M1 HSPC): **65** mo⁸

Today

- LATITUDE & STAMPEDE (ADT+ABI/P – M1 HSPC): not yet reached⁹⁻¹⁰



Kirurgisk og strålebehandling





1900---nu

- 1904 Først prostatektomi
- 1931 Først brachyterapi
- 1945 retropubic prostatektomi
- 1962 Ekstern radioterapi
- 1966 GS
- 1983 Nerve-bevarende prostatektomi
- 1988 TRUS
- 2001 laparoskopisk prostatektomi.



2017








Udfordringer

- Diagnostisk
- prognostisk
- Prædiktiv
- mPC



Biomarkører og PCa






Diagnostisk



Diagnostisk





Diagnostisk

	New generation (high-grade PCa)			Old generation (overall PCa)	
	SelectMDx ¹	4Kscore ^{2,3*}	ConfirmMDx ⁴	PCA3 ^{5-8*}	PHI ^{9,10}
AUC	0.86	0.82	0.74	0.66-0.69	0.70-0.77
NPV (%)	98	95	96	88-90	67-92
Risk of missing PCa (%)	2	5	4	10-12	8-33
Avoided biopsies (%)	53	36	-	44	36

1. Van Neste L et al. Eur Urol 2016;70:740-8; 2. 4Kscore Test Characteristics, available at <http://4kscore.com/wp-content/uploads/2016/09/Interpreting-your-Results.pdf>; 3. Parekh DJ et al. Eur Urol 2015;68:464-70; 4. Van Neste L et al. Prostate 2016;76:1078-87; 5. Gittelman M et al. J Urol 2013;190:64-9;
6. Wei JT et al. J Clin Oncol 2014;32:4066-72; 7. Haese A et al. Eur Urol 2008;54:1081-8; 8. Aubin SM et al. J Urol 2010;184:1947-52;
9. Filella X et al. Clin Chem Lab Med 2013;51:729-39; 10. De la Calle C et al. J Urol 2015;194:65-72



mPCa

Oligometastaser

Immunterapi

Genetiske



Oligometastaser

Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up

*Giorgio Gandaglia^{a,b}, Nicola Fossati^{a,b}, Armando Stabile^{a,b}, Marco Bandini^{a,b},
Patrizio Rigatti^c, Francesco Montorsi^{a,b}, Alberto Briganti^{a,b,*}*



^a Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; ^b Vita-Salute San Raffaele University, Milan, Italy; ^c Department of Urology, Advanced Urotechnology Center, Scientific Institute "Istituto Auxologico Italiano," Milan, Italy



Immunterapi

- Vaccination
- PDL-1
- Programmeret immune system

BRCA and PARPI





Andre områder

- Livskvalitet
- Livsstil
- Kost

Muligheder i DK

- 25 studier
- EMBARK (M0CSPC) (hele DK)
- ENZ i mCSPC (hele DK)
- PROfound (PARPI) (Odense)
- PRO-TEST (KBH)
- Biobanker



PerPros



PerPros

- Personaliseret behandling af PCa
- Sygehus Lillebælt, Sydvestjysk Sygehus, og
Sygehus Sønderjylland
- Blod og urin
- Opbevares på VS
- 5 år
- Palle Osther, Urologisk afd. VS.



Hvem kan være med...

- Alle mænd der **mistænkes** for prostatakræft og indkaldes til TRUS med biopsi
- Samtykke, blodprøver og urinprøve **FØR** biopsi



Tak

